Logo image of PHVS

PHARVARIS NV (PHVS) Stock Price, Quote, News and Overview

NASDAQ:PHVS - Nasdaq - NL00150005Y4 - Common Stock - Currency: USD

21.25  -0.18 (-0.84%)

PHVS Quote, Performance and Key Statistics

PHARVARIS NV

NASDAQ:PHVS (8/14/2025, 1:20:48 PM)

21.25

-0.18 (-0.84%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High26.33
52 Week Low11.51
Market Cap1.36B
Shares64.06M
Float44.17M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11/amc
IPO02-05 2021-02-05


PHVS short term performance overview.The bars show the price performance of PHVS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20

PHVS long term performance overview.The bars show the price performance of PHVS in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of PHVS is 21.25 USD. In the past month the price decreased by -6.83%. In the past year, price increased by 14.29%.

PHARVARIS NV / PHVS Daily stock chart

PHVS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 41.9 641.40B
JNJ JOHNSON & JOHNSON 17.46 420.38B
AZN ASTRAZENECA PLC-SPONS ADR 17.62 242.60B
NVS NOVARTIS AG-SPONSORED ADR 13.76 235.81B
NVO NOVO-NORDISK A/S-SPONS ADR 12.83 223.44B
MRK MERCK & CO. INC. 10.72 207.34B
PFE PFIZER INC 7.4 142.67B
SNY SANOFI-ADR 10.98 119.12B
BMY BRISTOL-MYERS SQUIBB CO 7.05 96.52B
GSK GSK PLC-SPON ADR 8.53 78.67B
ZTS ZOETIS INC 24.38 67.51B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.25 46.66B

About PHVS

Company Profile

PHVS logo image Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Company Info

PHARVARIS NV

Emmy Noetherweg 2

Leiden ZUID-HOLLAND NL

CEO: Berndt Modig

Employees: 83

PHVS Company Website

PHVS Investor Relations

Phone: 31712036410

PHARVARIS NV / PHVS FAQ

What is the stock price of PHARVARIS NV today?

The current stock price of PHVS is 21.25 USD. The price decreased by -0.84% in the last trading session.


What is the ticker symbol for PHARVARIS NV stock?

The exchange symbol of PHARVARIS NV is PHVS and it is listed on the Nasdaq exchange.


On which exchange is PHVS stock listed?

PHVS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PHARVARIS NV stock?

17 analysts have analysed PHVS and the average price target is 33.47 USD. This implies a price increase of 57.53% is expected in the next year compared to the current price of 21.25. Check the PHARVARIS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PHARVARIS NV worth?

PHARVARIS NV (PHVS) has a market capitalization of 1.36B USD. This makes PHVS a Small Cap stock.


How many employees does PHARVARIS NV have?

PHARVARIS NV (PHVS) currently has 83 employees.


What are the support and resistance levels for PHARVARIS NV (PHVS) stock?

PHARVARIS NV (PHVS) has a support level at 20.01 and a resistance level at 21.44. Check the full technical report for a detailed analysis of PHVS support and resistance levels.


Should I buy PHARVARIS NV (PHVS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PHARVARIS NV (PHVS) stock pay dividends?

PHVS does not pay a dividend.


When does PHARVARIS NV (PHVS) report earnings?

PHARVARIS NV (PHVS) will report earnings on 2025-11-11, after the market close.


What is the Price/Earnings (PE) ratio of PHARVARIS NV (PHVS)?

PHARVARIS NV (PHVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.62).


What is the Short Interest ratio of PHARVARIS NV (PHVS) stock?

The outstanding short interest for PHARVARIS NV (PHVS) is 2.37% of its float. Check the ownership tab for more information on the PHVS short interest.


PHVS Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to PHVS. When comparing the yearly performance of all stocks, PHVS is one of the better performing stocks in the market, outperforming 82.35% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PHVS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PHVS. The financial health of PHVS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHVS Financial Highlights

Over the last trailing twelve months PHVS reported a non-GAAP Earnings per Share(EPS) of -3.62. The EPS decreased by -28.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -61.49%
ROE -67.7%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-50.91%
Sales Q2Q%N/A
EPS 1Y (TTM)-28.22%
Revenue 1Y (TTM)N/A

PHVS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to PHVS. The Buy consensus is the average rating of analysts ratings from 17 analysts.


Ownership
Inst Owners50.44%
Ins Owners5.32%
Short Float %2.37%
Short Ratio7.54
Analysts
Analysts85.88
Price Target33.47 (57.51%)
EPS Next Y-25.95%
Revenue Next YearN/A